These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35240257)

  • 1. The influence of SLC22A3 rs543159 and rs1317652 genetic variants on metformin therapeutic efficacy in newly diagnosed patients with type 2 diabetes mellitus: 25 weeks follow-up study.
    Taheri R; Kazerouni F; Mirfakhraei R; Kalbasi S; Shahrokhi SZ; Rahimipour A
    Gene; 2022 May; 823():146382. PubMed ID: 35240257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Influence of OCT3 and MATE2 Genetic Polymorphisms in Poor Response to Metformin in Type 2 Diabetes Mellitus.
    Naem AAA; Al-Terehi MN; Ghafil FA; Ataya FS; Batiha GE; Alexiou A; Papadakis M; Welson NN; Hadi NR
    Endocrinol Diabetes Metab; 2024 Sep; 7(5):e486. PubMed ID: 39086121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the rs3088442 G>A SLC22A3 Gene Polymorphism and the Role of microRNA 147 in Groups of Adult Pakistani Populations With Type 2 Diabetes in Response to Metformin.
    Moeez S; Riaz S; Masood N; Kanwal N; Arif MA; Niazi R; Khalid S
    Can J Diabetes; 2019 Mar; 43(2):128-135.e3. PubMed ID: 30297296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients.
    Umamaheswaran G; Praveen RG; Damodaran SE; Das AK; Adithan C
    Clin Exp Med; 2015 Nov; 15(4):511-7. PubMed ID: 25492374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of clinical response to metformin in patients newly diagnosed with type 2 diabetes: a monotherapy study.
    Mahrooz A; Parsanasab H; Hashemi-Soteh MB; Kashi Z; Bahar A; Alizadeh A; Mozayeni M
    Clin Exp Med; 2015 May; 15(2):159-65. PubMed ID: 24740684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes.
    Phani NM; Vohra M; Kakar A; Adhikari P; Nagri SK; D'Souza SC; Umakanth S; Satyamoorthy K; Rai PS
    Pharmacogenomics; 2018 Jul; 19(11):905-911. PubMed ID: 29914345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between organic cation transporter genetic polymorphisms and metformin response and intolerance in T2DM individuals: a systematic review and meta-analysis.
    Peng A; Gong C; Xu Y; Liang X; Chen X; Hong W; Yan J
    Front Public Health; 2023; 11():1183879. PubMed ID: 37546319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients.
    Hou W; Zhang D; Lu W; Zheng T; Wan L; Li Q; Bao Y; Liu F; Jia W
    Mol Diagn Ther; 2015 Feb; 19(1):25-33. PubMed ID: 25573751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients.
    Raj GM; Mathaiyan J; Wyawahare M; Priyadarshini R
    Drug Metab Pers Ther; 2018 Dec; 33(4):175-185. PubMed ID: 30433870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Genetic Variants of SLC22A2 (rs662301 and rs315978) on the response to Metformin in type 2 Saudi diabetic patients.
    Alharbi AE; Ahmad MS; Damanhouri ZA; Mosli H; Yaghmour KA; Refai F; Issa NM; Alkreathy HM
    Gene; 2024 Nov; 927():148648. PubMed ID: 38852696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential increments of basal glucagon-like-1 peptide concentration among SLC47A1 rs2289669 genotypes were associated with inter-individual variability in glycaemic response to metformin in Chinese people with newly diagnosed Type 2 diabetes.
    Liang H; Xu W; Zhou L; Yang W; Weng J
    Diabet Med; 2017 Jul; 34(7):987-992. PubMed ID: 28321905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association study between changes in HbA1C with rs2250486 and rs67238751 genetic variants for SLC47A1 in newly diagnosed Iranian patients with type 2 diabetes mellitus: 6 months follow-up study.
    Semnani A; Kazerouni F; Kalbasi S; Shahrokhi SZ; Rahimipour A
    Endocrinol Diabetes Metab; 2023 May; 6(3):e410. PubMed ID: 36786075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis.
    Dujic T; Zhou K; Yee SW; van Leeuwen N; de Keyser CE; Javorský M; Goswami S; Zaharenko L; Hougaard Christensen MM; Out M; Tavendale R; Kubo M; Hedderson MM; van der Heijden AA; Klimčáková L; Pirags V; Kooy A; Brøsen K; Klovins J; Semiz S; Tkáč I; Stricker BH; Palmer C; 't Hart LM; Giacomini KM; Pearson ER
    Clin Pharmacol Ther; 2017 Jun; 101(6):763-772. PubMed ID: 27859023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin.
    Goswami S; Yee SW; Xu F; Sridhar SB; Mosley JD; Takahashi A; Kubo M; Maeda S; Davis RL; Roden DM; Hedderson MM; Giacomini KM; Savic RM
    Clin Pharmacol Ther; 2016 Nov; 100(5):537-547. PubMed ID: 27415606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of SLC22A2 (rs201919874) and SLC47A2 (rs138244461) genetic variants on Metformin Pharmacokinetics in Pakistani T2DM patients.
    Moeez S; Khalid Z; Jalil F; Irfan M; Ismail M; Arif MA; Niazi R; Khalid S
    J Pak Med Assoc; 2019 Feb; 69(2):155-163. PubMed ID: 30804576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
    Wu D; Li L; Liu C
    Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of the SLC47A1 Gene Variant With Responses to Metformin Monotherapy in Drug-naive Patients With Type 2 Diabetes.
    Kim H; Bae S; Yoon HY; Yee J; Gwak HS
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2684-2690. PubMed ID: 35639991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels.
    Zhang JP; Wang N; Xing XY; Yang ZJ; Wang X; Yang WY
    J Diabetes; 2016 Jul; 8(4):559-67. PubMed ID: 26331290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin.
    Kashi Z; Mahrooz A; Kianmehr A; Alizadeh A
    PLoS One; 2016; 11(3):e0151543. PubMed ID: 26978661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of
    Ortega-Ayala A; De Andrés F; Llerena A; Bartolo-Montiel CM; Molina-Guarneros JA
    Biomed Rep; 2024 Aug; 21(2):117. PubMed ID: 38938740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.